During the last decade, community-onset methicillinresistant Staphylococcus aureus (CO-MRSA) has emerged as a major public health concern worldwide. In the United States, CO-MRSA infections have been linked to a single dominant clone-pulsed-field gel electrophoresis (PFGE) type USA300, clonal complex 8, and spa type MBQBLO-that has specific microbiologic characteristics. Disease burden with this strain has grown rapidly: USA300 has been noted to cause up to 74% of staphylococcal skin and soft tissue infections in emergency departments [1] , and up to 44% of invasive staphylococcal infections in some regions [2] .
A major concern given this rapid clonal expansion is whether USA300 strains cause more severe infections. Reports describing increased virulence of the USA300 strain have included necrotizing fasciitis [3] , thrombosis [4, 5] , osteomyelitis [5] , purpura fulminans [6] , Waterhouse-Frederichsen syndrome [7] , a cholera-like syndrome [8] , and necrotizing pneumonia . These reports have suggested increased virulence of USA300 [30, 31] and have prompted intense media attention and public responses such as school closures [30, 32] . In the setting of influenza, pneumonia due to the USA300 MRSA strain has been associated with high morbidity and high mortality [22] [23] [24] [25] [26] [27] [28] [29] . Putative virulence factors in USA300 strains that may cause more virulent infections include PantonValentine leukocidin (PVL) [17] , arginine-catabolic-mobile-element [33, 34] , alpha-toxin [35, 36] , and phenol-soluble modulins [37] . In addition, USA300 is a sublineage of a S. aureus strain that has greater phenotypic virulence [38] .
Despite the case reports suggesting virulence, it is notable that population-based studies have failed to show any excess morbidity due to MRSA infections in the community [39] or in hospitalized patients [40] during this new epidemic. Therefore, it is unclear to what extent microbiologic findings of increased virulence translate into a greater burden of severe disease and whether the USA300 epidemic creates a risk of enhanced mortality.
We sought to measure the association between the USA300 strain and severe infections. To examine the effect of increasing CO-MRSA disease burden on hospital mortality and medical intensive care unit (MICU) hospitalization, we developed electronic surveillance criteria for severe CO-MRSA and used these criteria to assess epidemiologically the trends in severe CO-MRSA infection rates. To examine the relative virulence of USA300 compared with other strains of MRSA, we conducted a case-control study to examine the predictors of severe infection in individuals with CO-MRSA infection, with specific focus on the strain types and infection syndromes.
METHODS

Study Subjects and Setting
The study was performed at Stroger (Cook County) Hospital (CCH), a 464-bed public hospital in Chicago, Illinois. CCH is an urban hospital and primarily cares for uninsured or indigent individuals in Cook County, the second most populous county in the United States. CCH has the busiest emergency department in Chicago: In 2007, there were 125 350 emergency room visits, .600 000 ambulatory screening clinic (walk-in, urgent care, and scheduled) visits, and 24 495 admissions to CCH. In addition, there were 1045 MICU admissions, of which 962 (92%) occurred within 1 week of hospital admission.
The study was reviewed by our institutional review board; need for informed consent was waived.
Clinical and Microbiologic Database
Clinical and laboratory information for all patients at CCH with S. aureus infections are collected prospectively in a data warehouse [41] . Data captured include demographics, comorbidities (from discharge diagnosis codes), medication administration, hospital registration information, and length of stay. Algorithms are applied to the database to assess effectiveness of antimicrobial choice, severity of illness (APACHE II score), comorbidity (Charlson score [42] ), and outcomes.
Case Definitions
To track severe CO-MRSA infections, we modified a previously defined rule [41, 43] : Patients $18 years with CO-MRSA infections were identified as those with clinical isolates of MRSA from skin, soft tissue, joint, bone, bloodstream, sputum, pleural space, or other sterile sites (excluding urine), with detection as an outpatient or within the first 3 days of admission (ie, ,72 hours of admission). Clinically relevant severe illness was defined as CO-MRSA infection that resulted in patient transfer to the MICU within 1 week of admission or death within 1 week of admission. Only isolates obtained for clinical care were used; surveillance cultures and nares-positive cultures were excluded. Individuals were eligible for enrollment if care was given in either the emergency department or inpatient service.
Epidemiologic Study
For the epidemiologic study, all patients meeting the case definition of severe CO-MRSA infection were tracked from 2000 to 2007. To validate the electronic definition of severe illness, charts were reviewed for cases from 2004 to 2007. APACHE II score, cause of MICU admission and attribution to MRSA infection, and syndrome type were collected from chart review and compared with assessments from electronic medical record data.
Annual incidence rates were calculated using the CCH catchment area as the denominator [43] . Annual prevalence was calculated as a proportion of admissions to the hospital and the MICU. Rates were calculated for all patients meeting the case definition (ie, bloodstream infection, skin/soft tissue infection, and respiratory infection). The possible influence of influenza infections on severe MRSA infections was assessed by comparing infection rates during the influenza season (ie, October-March) with rates from the rest of the year.
Case-Control Study
Case patients and control patients were collected from 2004 to 2006. Chart reviews were conducted for all patients. Controls were selected from the cohort of CO-MRSA infections with admissions to the hospital but with no MICU admission or death in the 1 week after hospital admission, and were matched temporally 4:1 to cases (the 4 eligible control patients with infections closest in time to a given case patient's infection were selected).
Causes of hospital and MICU admission and death were ascertained through manual chart review; those patients with MICU admissions or deaths not attributable to MRSA infection were excluded from the case group. Patient-level data were collected including community risk factors (eg, whether home address was in a zip code with a higher density of communityassociated methicillin-resistant Staphylococcus aureus [CA-MRSA] infection [41] , residence type, drug use, or jail exposure), duration of symptoms before presentation to the hospital, clinical features (ie, characteristics of presentation including symptoms and signs of infection), APACHE II score, and laboratory and radiographic results. Patients were classified as having pneumonia (clinical impression of pneumonia based on treating physician's notes, or presence of fever, infiltrate, and positive sputum cultures), bacteremia (positive blood cultures), skin/soft tissue infection (clinical impression and/or positive cultures), endocarditis (positive blood cultures and echocardiographic demonstration of valvular vegetation), osteomyelitis (clinical impression or positive bone biopsy culture and radiographs), and septic arthritis (clinical impression or positive synovial fluid). Syndromes were not mutually exclusive. For individuals with pneumonia, all radiographs were reviewed, and patients were placed into 1 of 3 mutually exclusive categories: (1) lobar pneumonia: single involved lobe; (2) multilobar pneumonia: multiple lobes involved, inclusive of patchy multilobar infiltrates as well as necrotizing multilobar pneumonia, but without positive blood cultures; and (3) embolic pulmonary infiltrates: nodular or multilobar infiltrates with concurrent bacteremia. An electronic rule was developed to detect the presence of pneumonia due to CO-MRSA. This rule consisted of the presence of fever in addition to a positive respiratory culture with MRSA or presence of a positive blood culture with MRSA in patients with a concurrent chest radiography or chest computed tomography order. Based on a comparison of the findings of the rule with an independent, blinded, retrospective chart review conducted by 1 investigator (B. H.), the rule had a sensitivity of 92% and a specificity of 85%; in contrast, use of ICD-9 (International Classification of Diseases, Ninth Revision) coding data only (ICD-9 codes in the range 480-487) was less reliable to detect pneumonia, with a sensitivity of 31% and specificity of 97% in patients with positive sputum or blood cultures for MRSA. As such, the former rule (ie, presence of fever, a positive sputum or blood culture, and a radiograph) was used to detect pneumonia cases for purposes of trends and incidence measures.
Microbiologic Methods
Clinical isolates were stored for patients admitted after 2004. Clinical isolates were identified as S. aureus using routine methods [44] . Antimicrobial resistance was determined by automated broth microdilution (MicroScan, Dade Behring). Isolates were considered resistant to methicillin if the oxacillin minimum inhibitory concentraion was .4 lg/mL. One isolate per patient was studied for PFGE type, staphylococcal cassette chromosome (SCC) mec type, and presence of the PVL gene by standard methods [45] [46] [47] [48] .
Statistical Methods
Population-level analyses were conducted by calculating incidence of severe CO-MRSA infections per 100 000 people in the CCH catchment area and proportion of admissions to the MICU. Factors statistically associated with severe CO-MRSA infection in the case-control study were determined using Figure 1 . While total S. aureus admissions to the MICU were stable (Figure 2 ), MRSA as a cause of MICU admissions rose from 1.9% to 3.5% (relative prevalence, 1.94; 95% CI, 1.00-3.80). No differences were noted in comparisons of severe infection rates during the influenza season and other months (data not shown). The results of the case-control study are shown in Tables 1 and 2 . Patients with severe infection had more comorbidities and a higher mortality than controls (Table 1) . PFGE type USA300 was more prevalent in MRSA from control patients, reflecting the predominance in skin and soft tissue infections in this group. Table 2 shows the strain types associated with pneumonia, bacteremia, and skin and soft tissue infections.
Twenty-seven patients had septic pulmonary emboli in the assembled cohort. Of these, 18 (67%) were caused by USA300 strains and 18 (67%) were associated with severe illness. Of the 18 severe embolic pneumonias, 13 (72%) were caused by USA300. Table 3 shows the results of multivariate analysis. Patients with lobar pneumonia had a nearly 11-fold increased risk of early death or MICU admission attributable to MRSA; those with multilobar pneumonia showed a 12-fold increased risk of early death attributable to MRSA; and those with bacteremia demonstrated a 5.7-fold increased risk of early death or MICU admission attributable to MRSA. Interaction between strain type and syndrome in risk of severe illness was also evident. The highest risk was seen in patients who had pulmonary embolic infiltrates with bacteremia due to USA300 strains of MRSA, yielding a .30-fold increased risk of severe outcomes (Figures 3  and 4 ). Among cases, 13 patients (18%) had both USA300 infection and pulmonary embolic infiltrates compared with 5 patients (2%) in the control group. Interestingly, of these 13, only 3 had endocarditis detected though echocardiography. Other than in this specific clinical syndrome, USA300 strains were negatively associated with MICU admission or death, compared with other MRSA strains (eg, the USA100 strain).
DISCUSSION
Using a well-established S. aureus clinical data repository [43] , we evaluated the severity and impact of CO-MRSA infections. We Examinations of the impact of strain type on infection severity showed several strain-related effects. In particular, the USA300 PFGE strain was negatively associated with disease severity, with the exception of infections having septic pulmonary emboli with bacteremia. Bacteremia and pneumonia were independently and strongly associated with severe disease. Panton-Valentine leukocidin was not associated with severe disease in our patients. These findings suggest that patients with isolated skin or soft tissue infection or infection with USA300 strains are less likely to have more severe clinical courses, but those with evidence for pneumonia on initial evaluation have greater morbidity. Additionally, the finding of multilobar or nodular infiltrates that are suggestive of embolic disease carries the highest risk, particularly when due to the USA300 strain of MRSA.
Staphylococcal pneumonia, particularly in the setting of the USA300 MRSA epidemic, is a known cause of severe illness with high morbidity and mortality [22] [23] [24] [25] [26] [27] [28] [29] . For example, in the 2006-2007 influenza season, MRSA was found to be the cause of 10 cases of severe community-associated pneumonia with 6 deaths [28] . More recently, CA-MRSA was found to cause severe pneumonia in the setting of novel H1N1 in Australia; interestingly, in that study only 1 of 5 cases was caused by MRSA that carried PVL [22] . A study from Chicago of patients admitted from 2005 to 2007 found a 13% mortality from MRSA pneumonia with an absence of seasonality or association with influenza [49] .
Our findings expand on recent work to link MRSA strain types to disease severity, both in clinical appearance and based on microbiologic characteristics of involved strains. Strain-specific differences in disease manifestations have been b Control patients had nonsevere illness, defined as community-onset MRSA infection without medical intensive care unit admission or death.
c Other strains were as follows: Severe illness group, USA400 (2), USA500 (3), USA600 (2), USA700 (1), USA800 (3), nontypeable/SCCmec IV/PVL negative (1), nontypeable/PVL negative (1), nontypeable/PVL positive (3). Nonsevere illness group, USA400 (7), USA500 (11), USA600 (1), USA800 (9), nontypeable/SCCmec II/ PVL negative (2), nontypeable/SCCmec IV/PVL negative (3), nontypeable/PVL negative (5), nontypeable/PVL positive (9). demonstrated in active surveillance studies of invasive disease [2] , as well as in evaluations of hematogenous complications of infection [50] ; in both studies, USA100 strains were associated with greater invasiveness than other strains. In animal models of pneumonia, the expression of alpha-toxin has been found to be strongly associated with disease severity [35] ; in addition, the use of a vaccine protective against alpha-toxin has reduced severity of infection [36] . Further supporting this view is the finding that USA300 strains linked with pneumonia have been found to overproduce alpha-toxin in vitro [51] . Infection following influenza may be linked with overproduction of toxins in animal models [52] . Additional toxins have been found in community-associated MRSA strains USA300 and -400 that may also mediate illness severity [38] . The clinical syndrome of thrombosis, bacteremia, and pulmonary emboli, which has been associated with USA300 infections, may reflect the activity of novel toxins that promote risk of thrombosis [4, 5] . Clinical studies have shown better clinical outcomes [53] and both equivalent [40] and lower mortality [54] in patients with SCCmec IVa positive or USA300 MRSA infections. Whether the disparity in clinical outcomes among patients is the result of strain differences (eg, differences in expression of toxins) or differences in protein synthesis due to changes in the microenvironment of infection (ie, greater toxin production in the setting of pneumonia [45] ) is unclear. Our study is subject to several limitations. First, this study was conducted at a single center with high rates of USA300 MRSA, in an urban population. Further evaluation will be needed in multiple centers to confirm our findings. Our cohort, however, represents the busiest emergency room in the region and a major provider of care, as evidenced by the significant numbers of cases received during the observation period. A second limitation is the presence of residual confounding. We observed differences in our case and control groups in a variety of domains, including associations with prior hospitalization and comorbidities (eg, HIV, hemodialysis, and diabetes mellitus). Residual confounding may have been present, leading to underestimates of the association between MRSA strain type and the outcome of severe infection. The inverse relationship between severe outcomes and USA-300 infection that we found was strong, however, and given the strength of association, unlikely to be due only to bias or misclassification. Furthermore, the use of multivariable regression modeling and matching limits the impact of confounding and bias and provides adjusted estimates of association that permit examination of the risk due to strain type, independent of comorbidity.
In summary, our findings suggest that USA300 MRSA infections may have less severe outcomes than other MRSA strain types, with the exception of the syndrome of pneumonia with septic pulmonary emboli. Bacteremia or pneumonia with MRSA, regardless of strain type, represent the syndromes with the highest risk of complications or death. Despite the negative association with infection virulence and largely due to the extensive growth in infection rates with the organism, USA300 did substantially increase the overall rate of severe MRSA infections at our hospital as well as disease burden among MICU patients. Further study is needed to help establish the best methods to address these differences in clinical course, utilize recognition of differences to improve triage of patients, and reduce morbidity related to the epidemic of USA300 MRSA.
